Navigation Links
New discovery could dramatically reduce leishmaniasis treatment doses and side effects
Date:11/5/2013

The Amphotericin B (AmB) is the main active ingredient in the most effective drug used to treat leishmaniasis, a disease which in the Western world mainly affects dogs, but in developing countries affects over 12 million people, with more than 70,000 deaths per year. The cost of treating humans with AmB surpasses $5,000 per patient, the treatment is extensive (2-hour sessions every day during 21 days), and the side effects are frequent and many times patients must be hospitalised.

Researchers from the University of Miami, Florida and the Universitat Autnoma de Barcelona have developed a method which allows to drastically reduce the drug dose, since it improves its efficacy 83%, multiplies by 10 the capacity of the drug to attack cell infected by the parasite which provokes the disease, and significantly reduces the toxicity of the parasite. The method has been successfully tested on mice models of leishmaniasis.

The complex compound acts through the action of the PDD nanoparticle, a substance measuring some 10 nanometres in diameter which is fit into the active principle, Amphotericin B, and guides it selectively to the cells harbouring the parasite. Scientists observed how, while the usual complete dose of the drug requires over 12 days to reduce the skin lesions caused by the disease, one dose of the complex compound with only 17% of the complete dose of the drug improves skin lesions in two or three days. Moreover, the complex compound acts as a therapeutic vaccine which activates the immune system against the reservoir cells hosting the parasite.

The PDD substance has been used in previous trials with people with the aim of improving the response of their immune system to other diseases. Now there is a need for clinical trials with humans in order to verify its safety as an adjuvant in the treatment of leishmaniasis. If its safety in humans is confirmed, it will also reduce the cost of the treatment drastically, and this is a key element in reducing mortality rates in developing countries.


'/>"/>

Contact: Jordi Alberola
jordi.alberola@uab.cat
34-935-811-532
Universitat Autonoma de Barcelona
Source:Eurekalert

Related medicine news :

1. Biosimulation Market (For Drug Discovery & Development) Worth $1.2 Billion by 2017 - New Report by MarketsandMarkets
2. Discovery could lead to anti-clotting drugs with less risk of bleeding
3. International group finds 11 new Alzheimers genes to target for drug discovery
4. Biosimulation Market (Drug Discovery & Development) Worth $1.2 Billion by 2017 - New Report by MarketsandMarkets
5. New Case Management Order in New Jersey DePuy ASR Recall Litigation Extends Discovery to June 2014, More than 650 Metal Hip Lawsuits Filed in Consolidated Proceeding
6. The Producers of the In View Series Announce Upcoming Airing on the Discovery Channel
7. Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Discovery Conferences in Federal Vaginal Mesh Litigation, Bernstein Liebhard LLP Reports
8. LDM Global eDiscovery Professional, Jennifer Holt, is Awarded CEDS Certification
9. Cancer/Tumor Profiling Market (Personalized Medicine, Biomarker Discovery, Prognosis, Research) Worth $35.03 Billion by 2018 – New Report by MarketsandMarkets
10. Propofol discovery may help lead to development of new anaesthetics
11. American Brain Tumor Association Seeks Inventive Ideas for Research Discovery Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want ... their missing teeth can now have them placed by Dr. Manju Kejriwal, with or ... Cone Beam technology to increase the accuracy of each dental implant placement. The i-CAT ...
(Date:3/27/2017)... Austin, TX (PRWEB) , ... March 27, 2017 , ... ... , Edward Buckingham MD, and his colleague, Sudeep Roy, MD, was recently published ... on Bipolar Electrocautery Efficacy in Rhytidectomy” details Drs. Buckingham and Roy’s study on the ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, ... of Conformity for the Smart System® 20/20. CE Certification builds upon M&S's long-standing ... and specifications such as ANSI, ISO and proven test methods used in the ...
(Date:3/27/2017)... Lake Orion, Michigan (PRWEB) , ... March 27, ... ... loss results. The comprehensive weight management program at Women’s Excellence will help ... an initial evaluation and physical exam. The specialists at Women's Excellence will ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... and supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. For ... , “Increasingly, supply chain and value analysis professionals have a ‘seat at ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... AVIV, Israel , March 27, 2017 ... on oncology and immunology, announced today that AGI-134, an immunotherapy ... announced acquisition of Agalimmune Ltd., will be featured at the ... in Washington, DC to be ... ...
(Date:3/27/2017)... , March 27, 2017 The staggering ... the wealthiest countries have access to the latest treatment ... like the US, many patients have inadequate or no ... or skip therapy altogether. Access to modern cancer treatment ... affluent countries. The mission statements of ...
(Date:3/27/2017)... 2017 On Friday, benchmark US ... closed the trading session up 0.19%; the Dow Jones ... was down 0.08%. US markets made broad based gains ... in green. Pre-market today, Stock-Callers.com reviews these four Medical ... WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. (NASDAQ: ...
Breaking Medicine Technology: